enGene Therapeutics Inc. (ENGN) Operating cash flow 2022–2025
enGene Therapeutics Inc. (ENGN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$99.2MFY2025 · since FY2022: -$17.6M → -$99.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$99.2M | -105.5% |
| FY2024 | -$48.3M | -95.1% |
| FY2023 | -$24.7M | -40.6% |
| FY2022 | -$17.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ENGN financial trends
ENGN RevenueENGN Net incomeENGN Net marginENGN Gross profitENGN Gross marginENGN Operating incomeENGN Operating marginENGN Free cash flowENGN Capital expendituresENGN Return on equityENGN Stock buybacksENGN Dividends paidENGN Total assetsENGN Total liabilitiesENGN Shareholders’ equityENGN overview →